Business Context and Reporting Period
This Form 6-K filing by Icecure Medical Ltd. covers the month of July 2022, with the report dated July 25, 2022. The filing primarily serves to distribute a press release regarding a regulatory milestone for the Company's ProSense® technology.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report of a specific corporate event and does not contain financial statements or performance data.
Material Changes
The material change reported is the submission of a regulatory filing in Canada for the approval of ProSense®. The submission covers indications for the ablation of both benign and malignant breast tumors.
Guidance, Outlook, and Risks
The filing incorporates by reference the "Forward-Looking Statements" section from the accompanying press release (Exhibit 99.1). The text of this Form 6-K does not explicitly detail specific risks, contingencies, or unusual items beyond the standard incorporation of forward-looking language related to the regulatory submission.
Investor Verification Checklist
- Verify the status of the ProSense® regulatory submission in Canada via Health Canada or official regulatory databases.
- Review the full text of the press release (Exhibit 99.1) for specific details on the "Forward-Looking Statements" and associated risks.
- Confirm the specific indications approved or under review for benign versus malignant breast tumors.
- Check subsequent filings for updates on the approval timeline or any regulatory feedback received.